达格列净对2型糖尿病患者血压影响的系统评价(4)
[13] Kaku K，Inoue S，Matsuoka O，et al.Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control：a phaseⅡ multicentre，randomized，double-blind，placebo-controlled trial[J].Diabetes Obes Metab，2013，15(5)：432-440.
[14] Kohan D E，Fioretto P，List J，et al.Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment[J].J Am Soc Nephrol，2011，22(Suppl)：232A-233A.
[15] Ljunggren O，Bolinder J，Johansson L，et al.Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin[J].Diabetes Obes Metab，2012，4(11)：990-999.
[16] Calado J.Dapagliflozin，an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus[J].Drugs，2009，12(12)：785-798.
[17] Francis J，Zhang J，Farhi A，et al.A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria[J].Nephrol Dial Transplant，2004，19(11)：2893-2895.
[18] Sowers J R，Epstein M，Frohlich E D.Diabetes，hypertension，and cardiovascular disease：an update[J].Hypertension，2001，37(4)：1053-1059.
[19] Paromita K，Ian P，Richard D.The UK Prospective Diabetes Study(UKPDS)：clinical and therapeutic implications for type 2 diabetes[J].Br J Clin Pharmacol，1999，48(5)：643-648.
(收稿日期：2014-12-30) (本文编辑：欧丽), http://www.100md.com(陈丽等)
[14] Kohan D E，Fioretto P，List J，et al.Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment[J].J Am Soc Nephrol，2011，22(Suppl)：232A-233A.
[15] Ljunggren O，Bolinder J，Johansson L，et al.Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin[J].Diabetes Obes Metab，2012，4(11)：990-999.
[16] Calado J.Dapagliflozin，an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus[J].Drugs，2009，12(12)：785-798.
[17] Francis J，Zhang J，Farhi A，et al.A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria[J].Nephrol Dial Transplant，2004，19(11)：2893-2895.
[18] Sowers J R，Epstein M，Frohlich E D.Diabetes，hypertension，and cardiovascular disease：an update[J].Hypertension，2001，37(4)：1053-1059.
[19] Paromita K，Ian P，Richard D.The UK Prospective Diabetes Study(UKPDS)：clinical and therapeutic implications for type 2 diabetes[J].Br J Clin Pharmacol，1999，48(5)：643-648.
(收稿日期：2014-12-30) (本文编辑：欧丽), http://www.100md.com(陈丽等)